Evidence map›Paper›PMID 26048890›Full record

SynthesisClinical journal of the American Society of Nephrology : CJASN2015

Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.

Seychelle Yohanna, Ali M A Alkatheeri, Scott K Brimble, Brendan McCormick, Arthur Iansavitchous, Peter G Blake, Arsh K Jain

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Biocompatible dialysis fluids for peritoneal dialysis.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025
    Review
  9. Review
  10. Gastrointestinal disease in end-stage renal disease.World journal of nephrology · 2025
    Review
  11. Article
  12. Review
  13. Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.Journal of the American Society of Nephrology : JASN · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seychelle YohannaDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada;
Ali M A AlkatheeriDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada; Department of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia;
Scott K BrimbleDivision of Nephrology, McMaster University, Hamilton, Ontario, Canada; and.
Brendan McCormickDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Arthur IansavitchousDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada;
Peter G BlakeDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada;
Arsh K JainDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada; arsh.jain@lhsc.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesNeutral-pH, low-glucose degradation products solutions were developed in an attempt to lessen the adverse effects of conventional peritoneal dialysis solutions. A systematic review was performed evaluating the effect of these solutions on residual renal function, urine volume, peritoneal ultrafiltration, and peritoneal small-solute transport (dialysate to plasma creatinine ratio) over time. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Multiple electronic databases were searched from January of 1995 to January of 2013. Randomized trials reporting on any of four prespecified outcomes were selected by consensus among multiple reviewers.

resultsEleven trials of 643 patients were included. Trials were generally of poor quality. The meta-analysis was performed using a random effects model. The use of neutral-pH, low-glucose degradation products solutions resulted in better preserved residual renal function at various study durations, including >1 year (combined analysis: 11 studies; 643 patients; standardized mean difference =0.17 ml/min; 95% confidence interval, 0.01 to 0.32), and greater urine volumes (eight studies; 598 patients; mean difference =128 ml/d; 95% confidence interval, 58 to 198). There was no significant difference in peritoneal ultrafiltration (seven studies; 571 patients; mean difference =-110; 95% confidence interval, -312 to 91) or dialysate to plasma creatinine ratio (six studies; 432 patients; mean difference =0.03; 95% confidence interval, 0.00 to 0.06).

conclusionsThe use of neutral-pH, low-glucose degradation products solutions results in better preservation of residual renal function and greater urine volumes. The effect on residual renal function occurred early and persisted beyond 12 months. Additional studies are required to evaluate the use of neutral-pH, low-glucose degradation products solutions on hard clinical outcomes.

Indexed as

BiomarkersChi-Square DistributionCreatinineDialysis SolutionsGlucoseHumansHydrogen-Ion ConcentrationKidneyKidney DiseasesPeritoneal DialysisRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeUrinationUrodynamicsBiomarkersCreatinineDialysis SolutionsGlucosebiocompatibledegradation productsglucoseperitoneal dialysisresidual renal functionurine volume

Identifiers

PMID26048890
PMCPMC4527022

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.